Puertas B, Gonzalez-Calle V, Sureda A, Moreno MJ, Oriol A, Gonzalez E, Rosinol L, Lopez J, Escalante F, Martinez-Lopez J, Carrillo E, Clavero E, Rios-Tamayo R, Rey-Bua B, Gonzalez-Rodriguez AP, Dourdil V, De Arriba F, Gonzalez S, Perez-de-Oteyza J, Hernandez MT, Garcia-Mateo A, Bargay J, Blade J, Lahuerta JJ, San Miguel JF, Ocio EM, Mateos MV. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients. Haematologica. 2023 Oct 1;108(10):2753-2763. doi: 10.3324/haematol.2022.282490. PubMed PMID: 37102598; PubMed Central PMCID: PMC10542845.
AÑO: 2023; IF: 8.2